Detrás de los titulares sobre el cáncer

Estudio: Pruebas genéticas: recurso necesario para detectar mutaciones hereditarias en personas que padecen cáncer avanzado o metastásico

In a study of nearly 12,000 cancer patients with a variety of cancers, eight percent of participants with metastatic cancer had an inherited mutation in a cancer gene that qualified them for a targeted treatment approved by the FDA or for participation in a clinical trial. The majority of people with metastatic cancer were unaware that they had an inherited mutation, and had not receive gene-directed treatment to which their tumor may have responded. The study authors suggest that genetic testing for inherited mutations may be warranted for all patients with advanced or metastatic cancer. (posted 9/30/21)

Este artículo está disponible en español.

Actualización: Biopsias líquidas para detectar, vigilar y tratar el cáncer

Could a simple blood test change cancer detection, treatment and monitoring? Several companies are offering a type of blood test known as a liquid biopsy to detect multiple cancers at their earliest stages, monitor response to treatment and help choose the best treatment. Although progress has been made using liquid biopsies to treat cancer, these tests have not yet been shown to detect cancer early enough to save lives. (posted 9/29/21)

Este artículo está disponible en español.

Artículo: La perspectiva de las personas transgénero tras ser diagnosticadas con cáncer relacionado con el género

An ABC News article provides viewpoints and data that conveys the added stress experienced by transgender and gender-nonconforming people when they are diagnosed with gender-associated cancer (e.g., ovarian or prostate cancer) that does not match their gender identity. (posted 9/13/21)

Este artículo está disponible en español.

Estudio: La puntuación de la prueba tiene la capacidad de predecir cuáles pacientes con cáncer de próstata pueden omitir el tratamiento combinado sin correr riesgos.

This study shows that a test score that estimates the aggressiveness of a person’s prostate cancer may also identify the best treatment for patients. (posted 7/9/21)

Este artículo está disponible en español.

Estudio: Riesgos de padecer cáncer en personas con mutaciones hereditarias en el gen PALB2

In the largest study of people with inherited PALB2 mutations to date, the gene was linked to increased lifetime risk of breast cancer in women and men, ovarian and pancreatic cancer but not prostate or colorectal cancer. (posted 7/1/21)

Este artículo está disponible en español.

Estudio: Forma en la que el índice de masa corporal (IMC) puede afectar el efecto favorable del consumo de aspirina en la protección contra el cáncer colorrectal y de ovario

This study looked at the impact of daily aspirin use on the risk for many types of cancers and whether this effect can be modified by risk factors such as obesity, smoking, physical inactivity or a family history of cancer. Daily aspirin use: 

• lowered the risk for colorectal cancer, but this effect was lost as Body Mass Index (BMI) increased.
• lowered the risk of ovarian cancer risk among obese women.
• offered little or no protection against breast, endometrial or advanced prostate cancer.

(posted 3/19/21)

Este artículo está disponible en español.

Actualización: La FDA aprueba Orgovyx, la primera hormonoterapia por vía oral en su tipo, para tratar el cáncer de próstata avanzado

In December 2020, the FDA approved Orgovyx to treat advanced prostate cancer. The findings were based on the HERO clinical trial of more than 900 men. Data from this trial showed the new therapy was safer than standard androgen deprivation treatment for men with advanced prostate cancer and risk of cardiovascular disease. (2/18/21)

Este artículo está disponible en español.

Actualización: La FDA aprueba un nuevo medicamento para diagnóstico por imágenes para detectar la diseminación del cáncer de próstata

On December 1, 2020 the FDA approved a new type of imaging technology to confirm the spread of newly diagnosed prostate cancer that is suspected to be metastatic. The approval also includes use for confirming suspected recurrence in men who have rising PSA after treatment. The approval is based on two clinical trials that showed this new technique to be safe and consistent in accurately detecting cancer that has spread beyond the prostate gland. (1/7/21)

THIS INFORMATION HAS BEEN UPDATED on 5/10/2022:  On March 23, 2022 the U.S. Food and Drug Administration (FDA) approved a new drug called Pluvicto to treat patients with metastatic castration-resistant prostate cancer. ON the same day, the FDA also approved a new imaging drug called Locametz (a brand of Gallium 68 PSMA-11) for identification of those patients who would benefit from treatment with Pluvicto. Read about the FDA approval of Pluvicto and Locametz here.

Este artículo está disponible en español.

Artículo: La importancia de la diversidad de razas en estudios clínicos

This article by journalists Caroline Chen and Riley Wong looks at racial disparities between participation in clinical trials and the population of people with cancer. (11/6/18)

Este artículo está disponible en español.